Dr. Gorantla Addresses Unanswered Questions From the APHINITY Trial

Vikram C. Gorantla, MD
Published: Wednesday, Nov 28, 2018



Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Findings from the APHINITY trial led to the 2017 FDA approval of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and chemotherapy as an adjuvant treatment for patients with HER2-positive breast cancer who are at high risk for recurrence. The overall survival data from this trial are still maturing, which means that questions remain.

Gorantla raises the question of managing patients with residual disease. Additionally, he asks, what should be done for patients who received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab, and pertuzumab?

Long-term implications also need to be considered, as well as the cost of therapy. Cost involves not only physical and emotional toxicities, Gorantla explains, but also financial toxicities. That is something that is being closely examined now. As for physical toxicities, the biggest issue with pertuzumab was the rate of diarrhea—approximately a 7% increase compared with trastuzumab alone—but it can be easily managed, Gorantla says.
SELECTED
LANGUAGE


Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Findings from the APHINITY trial led to the 2017 FDA approval of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and chemotherapy as an adjuvant treatment for patients with HER2-positive breast cancer who are at high risk for recurrence. The overall survival data from this trial are still maturing, which means that questions remain.

Gorantla raises the question of managing patients with residual disease. Additionally, he asks, what should be done for patients who received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab, and pertuzumab?

Long-term implications also need to be considered, as well as the cost of therapy. Cost involves not only physical and emotional toxicities, Gorantla explains, but also financial toxicities. That is something that is being closely examined now. As for physical toxicities, the biggest issue with pertuzumab was the rate of diarrhea—approximately a 7% increase compared with trastuzumab alone—but it can be easily managed, Gorantla says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x